Takeda’s Nesina is a selective DPP-4 inhibitor for the treatment of type 2 diabetes. PPD’s compound partnering division collaborated with Takeda to develop the product. As part of
In addition to the demonstrated ability of Dynavax’s vaccine to generate cytotoxic T-cells and cytotoxic antibodies, the data showed that the universal components of Dynavax’s vaccine enhanced the
Facilitated by the Li Ka Shing Foundation (LKSF), the institute aims to develop new drugs, vaccines and diagnostic tests that would enhance human health world wide and reduce
Luye Pharma is expected to contribute its licensed rights to Crofelemer in China including Macao and Hong Kong for the indications of chronic diarrhea in people living with
As per the terms of the acquisition, an upfront payment corresponding to an enterprise value for MIP Technologies of 16MSEK will be made. In addition further payments based
In addition, the two entities have also signed an exclusive distribution agreement for the commercialisation of Daxas in the UK. As per the terms of the agreement, Nycomed
Charles River Laboratories International is a global provider of research models and associated services and of preclinical drug development services, while WuXi PharmaTech (Cayman) is a drug research
Transposagen Biopharmaceuticals said academic, pharmaceutical, and biotech scientists use these animals for drug discovery and development research and are expected to be sold under its new TGEM Rat
UCB said that FDA’s response is to an NDA Supplement, which was submitted by the company in June 2009, with a proposal for new refrigerated storage conditions to
Shire said that the lawsuit results from an Abbreviated New Drug Application (ANDA) filed by Teva for generic versions of 1mg, 2mg, 3mg and 4mg guanfacine hydrochloride extended
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.